Clinical trials: Blood Coagulation
Immune Thrombocytopenia, ITP
An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
This is a multi-center, observational, Phase 4 study in patients with Immune Thrombocytopenia (ITP) designed to describe the real-world effectiveness of Doptelet and assess the patterns of drug utilization to add to the knowledge…
- Trial name
- ADOPT (NCT04943042)
- Testing
- Avatrombopag
- Where
- 55 sites in Croatia, Czechia and 7 more
- Volunteers
- 199 people
- Sponsor
- Swedish Orphan Biovitrum
Platelet Activation, Thromboinflammation
Inflammation, Platelets and Sickle Cell Disease
Sickle cell disease (SCD) is an autosomal recessive genetic disorder linked to a single mutation on beta-globin chains. This leads to red blood cell deformation and chronic hemolysis which can result in vaso-occlusive events…
- Conditions
- Platelet Activation, Thromboinflammation, Sickle Cell Disease
- Trial name
- Il-Padre (NCT05646888)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Toulouse
Sepsis, Coagulation Disorder
The Impact of Coagulation Disorders on the Diagnosis and Prognosis of Sepsis
The study was a retrospective, single-center clinical study. From all patients admitted to the emergency ICU during the period of 2013.1.1-2019.12.31, the investigators screened all patients who met the criteria of 1) ≤7 days…
- Trial name
- NCT05998733
- Testing
- Early general coagulation function (5 items of coagulation) and thromboelastogram monitoring
- Where
- China
- Volunteers
- 552 people
- Sponsor
- Ruijin Hospital
Primary Immune Thrombocytopenia
A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)
This Phase 3 study is designed to evaluate the efficacy and safety of romiplostim in combination with predniso(lo)ne compared with predniso(lo)ne alone in adults with previously untreated Primary Immune Thrombocytopenia (ITP).
- Trial name
- ROMISTER (NCT07700238)
- Testing
- Romiplostim, Predniso(lo)ne
- Where
- 3 sites in United States
- Volunteers
- 126 people
- Sponsor
- Amgen
Liver Cirrhosis
Effects of Platelet Mimicking Nanoparticles in Patients With Cirrhosis
Haemostasis of cirrhotic patients is disturbed at different levels: primary haemostasis, coagulation and fibrinolysis, leading to a new haemostatic balance.
- Trial name
- HEMCITAP (NCT06050993)
- Testing
- Additional blood sampling at the same time and in addition of samplings already done for the patient's standard of care.
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coagulation; Intravascular, Fluid Electrolyte Disorders
Effect of Human Plasma Protein Transfusion With and Without Crystalloids During Major Liver Resection Surgeries
Evaluation of acid-base and electrolyte changes after administration of commonly used colloid solutions (plasma protein fraction contains 5% albumin), and crystalloids (saline 0.9% and lactated ringers solutions) is the primary…
- Trial name
- NCT05033704
- Testing
- 5% human plasma protein fraction (PPF)
- Where
- Qatar
- Volunteers
- 48 people
- Sponsor
- Hamad Medical Corporation
IgA Nephropathy, Renal Insufficiency, Chronic
Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
Global Burden of Diseases ranks chronic kidney disease (CKD) as the 12th leading cause of death, with an estimated 20% increase from 2010 to 2019.
- Conditions
- IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis, IGA Glomerulonephritis
- Trial name
- IA-GRACE-IgANT (NCT06676384)
- Testing
- Oral prednisolone and SoC, Gut-directed budesonide and SoC, Mycophenolate mofetil (MMF) and SoC
- Where
- 12 sites in India
- Volunteers
- 585 people
- Sponsor
- Christian Medical College, Vellore, India
Hemophilia B
Phase I/IIa Study of FIXFc in Hemophilia B Patients
The primary objective of the study is to assess safety of FIXFc at doses ranging from 1 to 100 IU/kg.
- Trial name
- NCT00716716
- Testing
- rFIXFc
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bioverativ Therapeutics Inc.
Von Willebrand Disease
Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease
The aim of this study is to assess the pharmacokinetics (PK), efficacy, and safety of Biostate® in subjects with Von Willebrand Disease (VWD).
- Trial name
- NCT00941616
- Testing
- Biostate®
- Where
- 5 sites in Bulgaria, Poland and 2 more
- Volunteers
- 22 people
- Sponsor
- CSL Behring
Blood Coagulation Disorders
ROTEM® Sigma Performance Evaluation - Method Comparison With Predicate Device and Reference Intervals
ROTEM® sigma is a new thromboelastometric coagulation analysis system. The new system is fully automated allowing for a simple and safe operation compared to its predecessor model ROTEM® delta.
- Trial name
- ROSI-EVA (NCT02379104)
- Testing
- ROTEM sigma
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Tem Innovations GmbH
Congenital Bleeding Disorder, Haemophilia A
Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients
The study has descriptive purposes, with aim of assessing how turoctocog alfa is used in the everyday practice and to provide a baseline for the management of haemophilia A and does not involve any change in the clinical…
- Trial name
- NCT06574984
- Testing
- Turoctocog alfa
- Where
- 7 sites in Iraq
- Volunteers
- 329 people
- Sponsor
- Novo Nordisk A/S
Contraceptive Usage, Coagulation
How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills
A randomized study is to learn more about how a supplement called DHEA (dehydroepiandrosterone) affects clotting factors in women taking combined oral contraceptive pills.
- Trial name
- COC+DHEA (NCT03418363)
- Testing
- DHEA Oral Capsule
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Covid19
Blood Coagulation Abnormalities in COVID-19 (Corona Virus Disease-19) Patients
The role of the coagulation parameters in predicting the severity of COVID-19 disease will be assessed
- Trial name
- NCT04982263
- Testing
- Blood coagulation profile
- Where
- 2 sites in Egypt
- Volunteers
- 125 people
- Sponsor
- Sohag University
Wiskott-Aldrich Syndrome
Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990
Wiskott - Aldrich syndrome (WAS) is a rare serious medical condition that causes problems both with the immune system and with easy bruising and bleeding.
- Trial name
- NCT02064933
- Where
- 43 sites in United States, Canada
- Volunteers
- 305 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cystic Fibrosis, Hemophilia A
Medication Adherence and Non-adherence in Adults With Rare Disease
The purpose of this study is to use the Medication Adherence Reasons Scale (MAR-Scale) to determine the extent of non-adherence to specific medications indicated to treat cystic fibrosis, hemophilia (A or B), idiopathic pulmonary…
- Conditions
- Cystic Fibrosis, Hemophilia A, Hemophilia B, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT04541875
- Testing
- MAR-Scale
- Volunteers
- healthy volunteers welcome
- Sponsor
- Xperiome
Severe Hemophilia A
Pharmacokinetics of rFVIIIFc at Two Vial Strengths
The primary objective of the study is to characterize the pharmacokinetics (PK) of rFVIIIFc administered at vial strengths of 1000 and 3000 IU in subjects with severe hemophilia A.
- Trial name
- NCT02083965
- Testing
- rFVIIIFc
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 19 people
- Sponsor
- Bioverativ Therapeutics Inc.
Immune Thrombocytopenic Purpura
Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP
This study is designed to compare the efficacy and safety of higher doses of Rituxan with a regimen combining standard doses of Rituxan + CVP in patients with chronic ITP who did not respond to or relapsed after standard doses of…
- Trial name
- NCT00774202
- Testing
- Rituxan, Cyclophosphamide, Vincristine, Prednisone, Higher Dose of Rituximab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Weill Medical College of Cornell University
Reversal of Coagulopathy
An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure
The purpose of this study is to evaluate efficacy, safety and tolerance of Beriplex® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by vitamin K antagonists in subjects who require…
- Trial name
- BE1116_3003 (NCT00803101)
- Testing
- Beriplex® P/N (Kcentra), Fresh frozen plasma
- Where
- 30 sites in United States, Belarus and 4 more
- Volunteers
- 176 people
- Sponsor
- CSL Behring
Hemophilia A
Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding
In this observational study researchers want to learn more about the safety of drug Jivi over a long period of time. Jivi (generic name: Damoctocog alfa pegol) is an approved blood clotting Factor VIII (FVIII) medication for the…
- Trial name
- HA-SAFE (NCT04461639)
- Testing
- Damoctocog alfa pegol (Jivi, BAY94-9027)
- Where
- 6 sites in Austria, Germany and 4 more
- Volunteers
- 62 people
- Sponsor
- Bayer
Immune Thrombocytopenic Purpura
Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP
The purpose of this study is to determine the response rate and response duration with the combination of low-dose rituximab and high-dose dexamethasone in the treatment of adult immune thrombocytopenic purpura.
- Trial name
- NCT01107951
- Testing
- Rituximab and dexamethasone
- Where
- Mexico
- Volunteers
- 21 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez